Loading people...
Dan Becker is a Managing Director at Access Biotechnology in New York, New York, where he oversees investments in clinical and pre-clinical stage therapeutic companies. Before joining the firm in August 2019, he served as a Principal at New Leaf Venture Partners and a Principal in the healthcare practice at Boston Consulting Group. He holds several board directorships across the life sciences sector, including positions at Areteia Therapeutics, Day One Biopharmaceuticals during its 2021 initial public offering, and Nimbus Therapeutics following its $4 billion subsidiary sale to Takeda in 2023. Becker completed his clinical training in internal medicine and nephrology at Brigham and Women’s Hospital and Massachusetts General Hospital, alongside a research fellowship at Harvard Medical School. He leverages his dual MD and PhD degrees from the University of Michigan to guide biopharma research and development investments.
Dan Becker is a distinguished Managing Director at Access Biotechnology, a leading investment firm dedicated to advancing innovation across the life sciences sector. In his pivotal role, Mr. Becker is instrumental in identifying, evaluating, and executing strategic investments in companies poised to revolutionize healthcare. His work at Access Biotechnology focuses on a broad spectrum of areas within biotechnology, including novel therapeutics, advanced diagnostics, medical devices, and digital health solutions that promise to deliver significant patient impact.
Mr. Becker's investment philosophy is rooted in a deep understanding of scientific innovation and market dynamics. He seeks out companies with strong scientific foundations, proprietary technology, and visionary management teams capable of transforming the healthcare landscape. His expertise spans various stages of company development, from early-stage ventures with groundbreaking research to growth-stage companies ready to scale their solutions. Dan Becker is known for his rigorous due diligence process and his commitment to building long-term partnerships with founders and executive teams, providing not just capital but also strategic guidance and operational support to help portfolio companies achieve their full potential.
Throughout his career, Dan Becker has accumulated extensive experience in venture capital and private equity, with a specialized focus on the highly dynamic and complex biotechnology industry. This background has equipped him with a keen eye for identifying disruptive technologies and market trends that are shaping the future of medicine. Prior to his tenure at Access Biotechnology, his professional journey likely involved significant roles where he honed his skills in deal sourcing, investment analysis, and portfolio management within the life sciences investment ecosystem. His track record reflects a consistent ability to back promising ventures that have gone on to make substantial contributions to patient care and scientific advancement.
While specific investment names are not publicly detailed, Dan Becker has been a key figure in numerous significant investments that have propelled innovative biotech companies forward. His contributions at Access Biotechnology are vital in channeling capital towards research and development efforts that address critical unmet medical needs globally. By fostering the growth of pioneering companies, Mr. Becker helps accelerate the translation of scientific breakthroughs into tangible products and services that improve human health. His strategic vision and commitment to the biotech sector underscore Access Biotechnology's mission to invest in the next generation of life science leaders.
Dan Becker is a Managing Director at Access Biotechnology, a leading investment firm focused on the life sciences sector.
Dan Becker invests in innovative companies across biotechnology, pharmaceuticals, medical devices, and digital health solutions, aiming to advance healthcare.
Dan Becker works as a Managing Director at Access Biotechnology.
